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A number of previous epidemiologic studies have suggested that infectious disease 
may be involved in the aetiology of childhood leukemia. Acute lymphoid leukaemia (ALL) is 
the most common type of cancer found in children and exposure to infections before or 
around birth may be associated with the risk of childhood ALL, but the findings are contra-
dictory. 
Previous studies reported that childhood acute lymphoblastic leukaemia can be linked 
with spatially heterogeneous environmental exposures. The presence of spatial clustering 
would be consistent with geographically localized environmental exposures over long periods 
of time. 
Clinical study: 
Seasonal influenza viruses and the pandemic influenza virus A (2009 H1N1) have 
caused significant morbidity and mortality around the world. In most patients, infection 
results in influenza-like symptoms without complications. In patients with cancer influenza 
infection can result in prolongation of chemotherapy and can cause serious complications, 
even death. A possible option to prevent influenza infection and its complications, is 
vaccination. After 2009, few studies investigated the immune response and safety of vaccines 




The aim of our first study was to investigate the presence of spatial clustering in 
childhood ALL that might arise as a result of persistent and localized environmental 
exposures using an independent population.  
To confirm the role of infectious aetiology in our second study the relationship be-
tween death from infectious disease of the respiratory system and the risk of ALL in children 
aged less than seven years was investigated. 
 
In our  prospective clinical study we evaluated the immune response and safety of 
concomittant trivalent-inactivated vaccine for seasonal influenza viruses (H1N1A, H3N2A 
and B), and monovalent-inactivated vaccine for the 2009 pandemic influenza virus A in 




PATIENTS AND METHODS OF OUR STUDIES 
 
I.1. Patients 
The area considered was South Hungary which includes two regions—South Transdanubia 
and South Great Plain. Children born between 1981 and 2000 were considered. Births and 
cases were assigned to six county districts within the study area. 
Registrations of first malignancies for children, born and diagnosed under age 5 years in 
Hungary before the end of 2005 were obtained from the Hungarian Paediatric Oncology Gro-
up (HPOG). The ALL registrations were based on address of residence of the family. Annual 
data on population of each settlement by gender in the study period were obtained from the 
Central Demographic Agency. 
I.2. Statistical Methods 
The Potthoff-Whittinghill (PW) and Moran I methods were used to test for spatial clustering 
and autocorrelation, respectively. 
Analyses were performed at two levels of areal resolution, counties and settlements. There 
were 6 counties with 906 settlements in the spatial clustering analyses. 
Statistical significance was taken as p<0.05 in all analyses. Similarly, the spatial distribution 
of cases in the study area was simulated to measure spatial autocorrelation index between the 
incidence rates in the geographical units using Moran I method. 
 
II.1. Patients 
The area considered was the same as in our first study. Children born between 1981 and2005 
were considered. Registrations of first malignancies for children, born in South Hungary and 
diagnosed under age seven years in Hungary before the end of 2010 were obtained from the 
Szeged and Pécs centres of Hungarian Paediatric Oncology Group (HPOG).  
The gender, year and county district of birth of all live birth registrations in the study period 
were obtained from the Central Demographic Agency.  
Both deaths from influenza (ICD9: 487, ICD010: J10-J11), deaths from chronic bronchitis 
(ID9: 490-496, ICD10 J41-J42) and deaths from pneumonia (ID9: 480-486, ICD10 J12-J18) 
were considered as exposures since the former were rare. From published statistics on infec-
tious deaths data were abstracted on: number of cases of influenza in Hungary and annually 
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total number of cases of influenza by county districts, hence the numbers of male and female 
flu cases in each county district in each year were calculated. 
II.2. Statistical methods 
 Poisson regression was used to investigate the relationship between risk of cancer and meas-




We enrolled 1 to 18-year-old children receiving chemotherapy for various types of cancer at 
the Pediatric Oncohematology Units of the University of Pécs and Semmelweis University of 
Budapest, from November to December, in the years 2009 and 2010. The children enrolled 
for the study were the consecutive patients treated in the respective centers. We exluded 
children with a recent history of 2009 pandemic A vaccination, confirmed diagnosis of the 
pandemic influenza A (2009 H1N1) virus infection prior to the vaccination, and past history 




Vaccine and Schedule 
In 2009, the pandemic vaccine (Fluval P -Omninvest, Pilisborosjeno, Hungary) was a 
monovalent vaccine, the seasonal influenza vaccine (Fluval AB7 – Omnivest) was a trivalent 
inactivated whole-virion influenza vaccine. In 2010, a polyvalent vaccine containing both the 
seasonal and the pandemic strains was produced by a method which met the requirements of 
the European Agency for the Evaluation of Medicinal Products for interpandemic influenza 
vaccines.  
Vaccination schedule was determined according to the recommendations of the Infectology 
Department of the Hungarian National Healthcare Advisory Board, based on data from the 
National Center of Epidemiology, Budapest, Hungary. Vaccination was performed 3-4 weeks 
after the last chemotherapy administration, and at least two days before the next 
chemotherapy treatment. 
Sample Collection and Serologic Analysis 
Once informed consent was obtained, a 3 mL blood sample was taken from each participant 
before vaccination and another 3-4 weeks afterwards, mostly via central venous catheter. The 
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serum was separeted by centrifugation, then immediately frozen and stored at -80 ˚C until the 
laboratory measurements on haemaglutination-inhibition (HAI) antibody titres were 
performed. All serologic tests were done at a single central laboratory (Department of 
Virology, National Center of Epidemiology, Budapest, Hungary). All paired sera were tested 
in duplicate on the same day using identical reagents. Seroprotective titer was defined as 
having a HAI antibody titer ≥40, and seroresponse was defined as having a fourfold or 
greater increase in HAI antibody titers after vaccination. Before vaccination, and on day 21-
28, blood samples were taken for haemagglutination-titer, immunoglobulin level and white 
blood cell count.  
Adverse Reactions and Medical Conditions 
Baseline assessments on day 0 included demographic data, medical history, and physical 
examinations were done. We checked all patients at least weekly by physical and laboratory 
(complete blood count) examination during the follow-up period, which lasted until the final 
blood collection for serologic study. Possible vaccine-related adverse events were monitored. 
On day 21–28, standard medical history and medications used during the days since the last 
visit were summerized, and physical examination was done before blood samples were 
collected. Safety variables were collected at follow-up visits through patient history and 
physical examination. 
Statistical Analysis 
Data were analyzed using paired and Student t-tests, chi-square-test (or Fisher exact-test) in 
the univariate analysis. Then the mixed model was applied to investigate the relationship 
between the outcome of vaccination (seroprotection / seroconversion) and the measured 
factors (immunoglobulin level, lymphocyte count, age). 
 
RESULTS OF OUR STUDIES 
 
There were 134 cases 73 (54.5 %) boys and 61 (45.5 %) girls) of ALL in those aged 
0–4 years in South Hungary in the spatial clustering study. Eight cases (five boys and three 
girls) of ALL were diagnosed before the age of 1 year. There were 547,034 live births in the 
study area during the 20 year-interval of 1981–2000. The overall incidence rate of ALL was 
4.90 per 100000 person years for children aged 0–4 years. The highest incidence rates of 6.79 




The incidence rate of boys (5.21 per 100000 person years) was non-significantly higher than 
the incidence rate of girls (4.57 per 100000 person years). The female incidence rates varied 
from 2.81 to 5.27 per 100000 person years, and the male incidence rates varied from 3.63 to 
8.30 per 100000 person years between counties. 
We found a statistically significant spatial clustering for all cases within smaller settlements 
which was attributable to clustering of male cases.  
The highest observed incidence rates of ALL at settlement level were 6.29 and 5.38 per 1,000 
persons in Baranya and Somogy counties between 1996 and 2000, respectively. 
A significant spatial autocorrelation was found in the incidence of ALL for all cases in the 
Moran analysis (I=0.18, p=0.0012) over the whole period. The global Moran (I=0.14) 
statistic was significant (p=0.028) among boys, but non significant among girls (I=0.04, 
p=0.16). 
 
In our second study the total numbers of deaths were during the 20 year 26753, 5649 
and 770 from chronic bronchitis, pneumonia and influenza, respectively. The median mortali-
ty rate of chronic bronchitis was 815.8 / 100000 person years (inter quartile range (IQR): 
[511.5–1280.1]/ 100000 person years), of pneumonia was  176.1/ 100000 person year (IQR: 
[144.0–232.6 ] / 100000 person year, and of influenza was 22.6 / 100000 person year (IQR: 
[18.5–37.7] / 100000 person year).  
The study included 176 cases 92 (52.3%) boys and 84 (47.7%) girls) of ALL in those aged 0-
6 years in South Hungary. Eight cases (five boys and three girls) were diagnosed before the 
age of 1 year. There were 547.034 live births in the study area during the 20 year-interval of 
1981-2000. The overall incidence rate of ALL was 5.37 per 100,000 person years for children 
aged 0-6 years. The incidence peak age at diagnosis of ALL was 2-5 years. 
There was a moderate risk of ALL disease exposed around birth to higher levels of mortality 
of the chronic respiratory diseases among children aged 2-5 years (p=0.035) and aged 2-6 
years (p=0.033).  We found a significant trend for risk of ALL disease exposed around birth 
to higher levels of mortality of pneumonia among children aged 2-5 years (p=0.010) and aged 
2-6 years (p=0.025). On the other hand these trends were significant only in girls (p=0.08), 
not in boys. Nevertheless, significantly increased risk of childhood ALL was detected among 
children under one year of age exposed around the birth to higher levels of mortality from 
influenza (OR for trend was 1.05; 95%CI [1.01 – 1.10]; p=0.012).  This increased risk was 
detected in girls (OR: 1.22; 95% KI [1.05 – 1.42]; p=0.009) , but not in boys (OR=0.91; 95% 





In our clinical investigation twenty-seven pediatric patients with cancer (15 males and 
12 females) completed the study. Their median age was 10.4 years (range 2.83 – 18.16 
years). The underlying diseases were leukemia (10 patients), lymphoma (2 patients), and 
solid tumor (15 patients). Fourteen patients were younger than 10 years old, and therefore 
received 0.25 mL of vaccine, while the remaining thirteen patients received 0.5 mL of 
vaccine. All 27 patients received chemotherapy within 1 month before vaccination, and all 
continued to receive scheduled chemotherapy after vaccination. Five were undergoing 
maintenance therapy. The remaining twenty-two were receiving intensive cytostatic 
treatment. In the latter cases, cytostatic treatment was administered only on the 3rd day after 
vaccination. 
Prevaccination seroprotective rates were significantly higher for seasonal influenza viruses 
H1N1 and H3N2, than for seasonal B and pandemic H1N1Swl (p<0.001). The differences 
between pre- and post-vaccination seroprotective rates in the case of Influenza B was 
significant (p=0.038). No significant differences were found between pre- and post-
vaccination seroprotective rate changes with other viruses (H1N1Swl p=0.064, H1N1 
p=0.277, H3N2 p=0.160). We compared the pre- and post-vaccination seroprotective rate 
changes and seroresponse rate of each seasonal Influenza virus with the pandemic H1N1Swl 
virus by a paired t-test. Neither HAG seroprotective rate changes, nor seroconversion for 
seasonal H1N1-H1N1Swl, H3N2-H1N1Swl, B-H1N1Swl were significant using this method.  
Comparing the effect on seroprotection change and seroconversion of each virus type 
combined with age category (over and below 10 years) using binary logistic regression, here 
was no significant difference either in seroprotection rate changes or in seroconversion, 
between the different influenza virus strains. Lymphocyte counts at the time of vaccination 
were between 0.44 G/l and 7.77 G/l (median: 1.34 G/l). Lymphocyte count above 1.0 G/l was 
significantly correlated with immune response after influenza vaccination (p=0.018). On the 
other hand, lymphocyte count above 1.0G/l did not have a significant influence on 
seroprotection change. These results were independent of virus strain. The immunoglobulin 
G (IgG) levels at the time of vaccination were between 4.27 g/l and 12.8g/l (median: 7.32 
g/l). Most (14/19) of the patients, had age related normal level of IgG at the time of 
vaccination. This was significantly correlated with immune response after influenza 
vaccination, independently of virus strain (p=0.01). Age related normal IgG level did not 
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have a significant influence on seroprotection change (p=0.063). Type of malignancy and 
status of cancer therapy (maintenance or intensive treatment) did not significantly influence 
seroprotection change or seroconversion. There were no breakthrough influenza infections, 
and neither of the non-vaccinated patients suffered from influenza during this period. 
Adverse Reactions 
We recorded no local adverse reactions (e.g. injection site induration, erythema, swelling, or 
warmth). One case of malaise (3.7%) was detected on the day after vaccination. No medical 




In our first epidemiological study, significant spatial clustering for all cases at the 
smaller settlement level was found which was attributable to clustering of male cases. This 
finding partly confirms our previous results where different pattern of risk to acute lymphoid 
leukaemia was found in boys and girls aged less than 5 years and was attributable to an 
association between the risk of childhood leukaemia and population mixing, which has been 
interpreted as evidence of an infectious aetiology. South Hungary, the area considered, covers 
nearly a quarter of the childhood population of the country providing a representative sample 
of Hungarian children. Thus, our study included a large sample of a population over a 20 year 
period of time. 
It is important to note that the spatial clustering found amongst children could have arisen by 
chance or it could be explained by lifestyle factors, characteristics of the residential area or 
another unmeasured heterogeneous geographical factor. However, the applied clustering 
analyses have used an optimal statistical method for detecting the global occurrence of 
localized aggregations of cases. As far as we are aware, this was the first epidemiological 
study reporting the effect of spatial clustering of ALL for boys and girls separately. 
Our second study included a large sample of a population over a 20-year period of 
time. In our study the peak of childhood leukemia cases diagnosed less than seven year were 
selected to analyze infectious effects on developing ALL. In spite of the apparent limitation 
of our study that we have not had data of other infectious agents, including measles, chicken 
pox, and adenovirus and we have applied an indirect measurement on influenza, this 20-year 
long study support new evidence to understand the different pattern of female and male 




The purpose of our clinical study was to investigate the efficacy and safety of 
concomittant trivalent-inactivated vaccines for seasonal influenza viruses (H1N1A, H3N2A, 
and B), monovalent-inactivated vaccine for the 2009 pandemic influenza virus A, and a 
combined (pandemic and seasonal vaccine - polyvalent) vaccine in 2010, in children with 
cancer undergoing chemotherapy. Vaccinations (H1N1A, H3N2A, B and pandemic 
H1N1Swl) produced no significant adverse events, but resulted in limited serosresponse rates 
(22%, 37%, 22% and 30% respectively). These results were similar to response rates reported 
earlier for influenza viruses, and recently for pandemic influenza virus A. Our patients were 
receiving chemotherapy at the time of vaccination, thus limited seroprotection changes and 
serosresponse rates were expected. The proportion of patients achieving protective antibody 
levels to individual viral strains following vaccination has been reported to be 29%–75% in 
children on chemotherapy. In the present study all children were receiving chemotherapy, 
and an immune response was observed in 22%–37% of children. There was no significant 
difference in either post-vaccination seroprotection change or seroconversion of the different 
seasonal influenza  
viruses when compared with the pandemic H1N1Swl virus, results similar to those obtained 
in healthy people. There is contraversial data regarding lymphocyte count, and serum IgG 
level, as factors responsible for immune response after administration of influenza vaccine in 
children with cancer undergoing chemotherapy. The present study demonstrates that, for both 
seasonal viruses and the pandemic H1N1 virus, lymphocyte count above 1.0 G/l, and normal 
IgG level has significant influence on the immune response after vaccination.  
 
SUMMARY OF THE NEW FINDINGS PRESENTED IN THE THESIS 
1. We found a statistically significant spatial clustering in childhood ALL in South-Hungary 
for all cases within smaller settlements which was attributable to clustering of male cases.  
2. To our knowledge we proved at first a gender-difference in spatial clustering in childhood 
ALL.  
3. We described a significant association between incidence of ALL among children aged 2-5 
years (incidence peak population of childhood ALL) and mortality of the chronic respiratory 
diseases and pneumonia.    
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4. We could have determined a significantly increased risk of ALL among infants exposed 
around the birth to higher levels of mortality from influenza. 
5. We could have determined the safety of concurrently given pandemic H1N1 and seasonal 
Infuenza vaccine in children during chemotherapy.  
6. We proved no difference between seasonal and pandemic Influenza vaccination neither in 
HAG seroprotective rate changes, nor in seroconversion rates.  
7. We showed that in chemotherapy treated children lymphocyte count above 1.0 G/l is 
significantly correlated with immune response after influenza vaccination. 
8. We observed that in chemotherapy treated children age related normal level of IgG at the 
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